
23 segments available
Is it real or science fiction to dream of being able to treat… getting old? In this episode, we discuss with Dr. Thomas Rando from Stanford (who directs the Glenn Center for the Biology of Aging), Kristen Fortney, CEO of BioAge, and a16z’s general partner Vijay Pande where we are in the field of “geroscience” — the idea of studying, well, aging itself, and aging as the root risk for all aging related disease. Far from science fiction, recent discoveries have given us a whole crop of promising breakthroughs to treat aging, such as parabiosis (young blood infused into old blood), senolytics, and rapamycin, and more. What we’re beginning to see is a fundamental shift away from the idea of searching for immortality and towards the idea of increasing "health span” — where prevention means much more than eating healthier or exercising more. Are we moving from Dx to Rx to — perhaps Px? What will it look like when anti-aging therapies actually begin to be delivered to us: small molecule or protein or an antibody — or something else entirely? A pill or a blood transfusion treatment? A vaccine for aging?
In this segment, the hosts introduce the concept of geroscience, the study of aging as a major risk factor for diseases. They clarify that the focus is not on achieving immortality but on extending health span, emphasizing the importance of living a longer, healthier life rather than merely increasing lifespan.
"hi and welcome to the a 16z podcast I'm Hannah and today we're talking about the science of life extension are we finally just around the corner from a treatment for getting old in this episode we tal..."
Dr. Thomas Rando discusses the critical distinction between life extension and health span extension. He explains that while life extension may imply immortality, the real goal is to enhance health and reduce the period of disability at the end of life. This segment highlights the importance of focusing on health rather than just longevity.
"dr. Thomas Rando from Stanford who directs the Glenn Center for the biology of Aging then a 16-0 partner Vijay Pandey joined by Kristin Fortney CEO of bio age so let's start off with a simple question..."
Dr. Rando outlines the significant changes in aging research over the past decades, particularly the emergence of geroscience. He emphasizes the potential for interventions that could slow aging and delay age-related diseases, marking a shift towards preventive health strategies that were previously unimaginable.
"distinction because so much experimentation goes into lifespan extension in animals but really the translation is making people healthier longer yes they may live a little longer but what we really wa..."
This segment delves into the recent scientific advancements in aging interventions, including caloric restriction and gene interventions in model organisms. Dr. Rando discusses how these findings are paving the way for potential applications in humans, highlighting the excitement surrounding the current state of aging research.
"in the field of aging across say the decades there's a pivot happening now that I think is really remarkable it's it's changed a lot in the last two decades and then every five years you see another b..."
The conversation shifts to the role of biomarkers in aging research. Dr. Rando explains how genomic data can help measure biological age and predict the effectiveness of interventions, potentially accelerating the discovery of new therapies for human aging. This segment emphasizes the importance of understanding healthiness over chronological age.
"exciting about the state of the field right now the field has focused in academia on invertebrate models because they're sort of more attractable they have shorter life spans but because of sort of ne..."
Dr. Rando discusses the intriguing concept of using young blood to reverse aging effects in older organisms. He explains the scientific basis behind this idea and its historical roots, emphasizing the potential for circulating factors in blood to promote youthfulness and the implications for developing anti-aging interventions.
"treatment we have would be from the pop culture perspective like caloric restriction this idea of old blood and new blood some of the actual science has roots in old ideas and some of it is based in c..."
In this segment, the discussion focuses on senescent cells and their impact on aging. Dr. Rando highlights recent research showing that eliminating these cells can significantly boost lifespan in mice, underscoring the potential for targeting senescence as a strategy for extending health span and longevity.
"fertile for extending the health span of a life yeah there's a few different things that have shown promise in a million systems so there's a pair of iosys as Tom discusses his which is his expertise ..."
Dr. Rando speculates on the future of senolytic therapies as small molecule treatments. He discusses the unknowns regarding long-term use and potential downsides of eliminating senescent cells, emphasizing the need for further research to understand the balance of benefits and risks in aging therapies.
"it speaks um one question I have which is what would this look like would this look like a small molecule that actually would if you take it every day as some sort of supplement would would it help yo..."
This segment explores various innovative approaches to aging therapies, including protein treatments and antibody therapies. Dr. Rando discusses the potential for developing vaccines against aging factors, highlighting the exciting possibilities for future treatments that could enhance health span.
"turned into a pill mm-hmm the plasma coming from the para bios's worked that idea of plasma infusions you know actually can be done but it's much more invasive you have to inject plasma to people we r..."
The discussion shifts to the impact of modern technologies like data science and machine learning on aging research. Dr. Rando emphasizes the importance of non-invasive technologies for monitoring aging and how bio banks can accelerate our understanding of human aging through advanced analytics.
"of benefit I can imagine a science-fiction story right now because you can develop an antigen for that antibody and now you have a vaccine for aging you know the role of data because not just right ab..."
Dr. Rando explains how bio banks with stored human samples and electronic health records can be utilized to predict aging outcomes. This segment highlights the potential of integrating historical data with modern technologies to enhance our understanding of aging and longevity.
"for the first time did they accelerate it I mean are we still in a position where we have to actually watch people age you know decades to know whether that first there is a way around that so you can..."
The conversation focuses on rapamycin, a drug that has shown promise in extending lifespan in mice. Dr. Rando discusses its potential implications for human aging therapies and the need for more extensive testing of various drugs to discover effective aging interventions.
"excited about that and the second answer to that question is that I think that aside from accelerating research into human aging it's also accelerating research into mammalian aging in general because..."
Dr. Rando addresses the unique challenges faced by biotech companies in developing aging therapies. He discusses regulatory hurdles and the complexities of proving efficacy for drugs aimed at slowing aging, emphasizing the need for clear FDA indications.
"system for you know evaluated many more drugs than thirty so I think there's a lot of low-hanging fruit there what is intriguing about the ability to get this information from blood whether we're talk..."
The segment concludes with a discussion on metformin, a diabetes drug that may enhance lifespan. Dr. Rando highlights epidemiological data suggesting its potential benefits for longevity, particularly in diabetic patients, and the broader implications for aging research.
"excellent point like you know biotech companies drug discovery companies have a lot of challenges to face and I think there's even more in the case of an aging company because even if we do discover a..."
This segment delves into the concept of aging as a central risk factor for multiple diseases, including heart disease and Alzheimer's. The speakers argue that by targeting aging itself, rather than individual diseases, we can potentially delay the onset of various age-related conditions, marking a significant shift in medical treatment paradigms.
"the notion is maybe everyone will live longer if they take the med foreman so especially in people who have diabetes but also in people who do what epidemiologic data is that so there's no epidemiolog..."
The discussion highlights a fundamental shift in the approach to healthspan, moving from traditional prevention methods to innovative therapeutics aimed at aging. The speakers emphasize the importance of regulatory changes to accommodate these new preventive strategies, which could revolutionize how we think about aging and health.
"really it's it's the notion is that it's preventing the notion is that that agent whether the concept that's out there's aging is the major risk factor for all of these nieces heart disease cancer Alz..."
In this segment, the speakers address the historical context of FDA regulations regarding aging therapies. They discuss the challenges of approving treatments for healthy individuals and the evolving mindset that may allow for preventive therapies to be developed and tested more broadly.
"delay the onset of all these stabilities so that's at the root cause right all of these approaches are getting at the root cause not all the symptoms and diseases that are associated that so how does ..."
The conversation explores the potential future of aging treatments, including the possibility of delivering therapies to healthy individuals. The speakers discuss ongoing trials and the hope that regulatory constraints will continue to loosen, paving the way for innovative therapies that could benefit a wider population.
"be approved for treatment of healthy people and is that because of the time because it takes so long or is it no it's just just the historical context and i remember so probably 15 years ago i was tal..."
This segment focuses on the strategic decisions biotech companies must make when selecting disease indications for anti-aging drugs. The speakers discuss the importance of identifying relevant indications that can facilitate regulatory approval while also considering broader applications of these therapies.
"shift a little bit well even this tame trial being discussed and being presented to the FDA and the FDA discussing it is already a major step forward I mean that that would not have happened 10 years ..."
The discussion concludes with speculation on how anti-aging therapies might be delivered to the public, including the potential for plasma infusions from young donors. The speakers highlight ongoing trials and the implications for treating conditions like early-onset Alzheimer's, emphasizing the innovative approaches being explored in the field.
"prevention slowing drug test it in these conditions if it works then you may be on to something so can you pick multiple ones and are there certain ones that are that tend to crop up over and over aga..."
This segment explores the potential economic impact of successful anti-aging therapies on global healthcare systems. The speakers discuss how delaying age-related diseases could lead to significant cost savings for governments and the need for a shift in societal perspectives on health preservation. They compare these therapies to safety measures like seatbelts, emphasizing the importance of proactive health strategies.
"early onset Alzheimer's disease so it's in trial and we don't you know don't know if it'll work yet but but so in theory in a short time plasma infusions for certain diseases might be as might be a tr..."
The discussion delves into the societal changes that may occur if humans were to gain an additional 40 years of life. The speakers consider the implications for demographics, family structures, and workforce participation. They highlight the need for society to adapt to these changes, particularly in terms of retirement age and family planning, and how this could reshape our understanding of life stages.
"to be thought in a different way and that it's you know more akin to like seatbelts and airbags but but there is also a cost I mean say we did all add 40 years to our lives you know which would be ama..."
In this concluding segment, the speakers reflect on families with heritable traits of exceptional longevity, discussing how these individuals maintain active and healthy lives well into their hundreds. They emphasize the desire for longer life without increased instability and the lessons we can learn from studying these populations. This segment encapsulates the hope for a future where longevity is coupled with vitality.
"and we think about our very humanity in these terms and what does it mean when you when we when we open that and how we think about humanity . we're still not talking about infinity there's a big diff..."